Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Cross-over Study With 2 Treatments (Fasting and After Meals), 3 Periods, 2 Sequences, and an Adaptive, Two-stage Design to Evaluate the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets at a Single Dose in Healthy Volunteers

NCT05295121 is registered in ClinicalTrials.gov with Valenta Pharm JSC as lead sponsor.

NCT NCT05295121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05295121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Cross-over Study With 2 Treatments (Fasting and After Meals), 3 Periods, 2 Sequences, and an Adaptive, Two-stage Design to Evaluate the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets at a Single Dose in Healthy Volunteers
Lead sponsor
Valenta Pharm JSC
Phase
Phase 1
Overall status
Completed
Start date
February 10, 2022
Completion date
March 17, 2022
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy